Drug Topics

CONTINUE TO SITE >

OR WAIT 15 SECS

Cardiovascular Clinical Consult DiabetesGenericsGut HealthImmunizationOncologyRespiratoryShinglesTechnologyThoughtSpot 2020

AnticoagulantsAutoimmune DiseasesBiosimilarsCardiovascular DiseaseCBDCOPD ManagementCoronavirusDermatologyDiabetesGenericsGut HealthImmunizationInfluenzaOncologyPain ManagementPediatricsRespiratoryShingles

All NewsAssociation NewsClinical NewsLegal NewsManaged Care NewsNew ProductsTechnologyViewpoints

Expert InterviewsMedical World NewsPodcasts

Chain PharmacyCommunity PracticeHealth Systems

Conference CoverageConference Listing

eNewsletterPrint Subscription

Advertise
Editorial
Contact Us
Terms and Conditions
Privacy
Do Not Sell My Personal Information

© 2020 MJH Life Sciences and Drug Topics. All rights reserved.

Spotlight

Cardiovascular Clinical Consult
Diabetes
Generics
Gut Health
Immunization
Oncology
Respiratory
Shingles
Technology
ThoughtSpot 2020

ClinicalSee All >

Anticoagulants
Autoimmune Diseases
Biosimilars
Cardiovascular Disease
CBD
COPD Management
Coronavirus
Dermatology
Diabetes
Generics
Gut Health
Immunization
Influenza
Oncology
Pain Management
Pediatrics
Respiratory
Shingles

Advertise
Editorial
Contact Us
Terms and Conditions
Privacy
Do Not Sell My Personal Information

© 2020 MJH Life Sciences^™ and Drug Topics. All rights reserved.

Cimzia approved for signs and symptoms of Crohn's disease

May 12, 2008

UCB receives FDA approval for certolizumab pegol (Cimzia).